Revolution Medicines to Participate in November 2026 Investor Conferences
Revolution Medicines (RVMD) announced that CEO and chairman Mark A. Goldsmith will participate in two investor conferences in November 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Revolution Medicines (RVMD) announced that CEO and chairman Mark A. Goldsmith will participate in two investor conferences in November 2026.
His fireside chats are scheduled for the Guggenheim Healthcare Innovation Conference on November 10 at 8:30 a.m. ET and the Jefferies Global Healthcare Conference in London on November 16 at 5:30 a.m. ET. Live webcasts and replays will be available on the company’s website, with replays accessible for at least 14 days.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will participate in two upcoming investor conferences.
Details of the company’s participation are as follows:
- 3rd Annual Guggenheim Healthcare Innovation Conference 2026
- Fireside Chat Date/Time: Tuesday, November 10 at 8:30 a.m. ET
- Jefferies Global Healthcare Conference in London
- Fireside Chat Date/Time: Monday, November 16 at 5:30 a.m. ET
To listen to a live webcast of any of these events, or access archived webcasts, please visit: https://ir.revmed.com/events-and-presentations. Following the live webcasts, replays will be available on the company’s website for at least 14 days.
About Revolution Medicines, Inc.
Revolution Medicines is a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of oral RAS(ON) inhibitors designed to directly target the active, cancer-driving state of RAS. Founded on rigorous scientific inquiry and a willingness to challenge long-held assumptions, Revolution Medicines is committed to changing the trajectory of disease for patients with RAS-addicted cancers worldwide. For more information, visit www.revmed.com and follow Revolution Medicines on LinkedIn, X (Twitter) and Instagram.
Revolution Medicines Media & Investor Contact:
media@revmed.com
investors@revmed.com
